Kezar Life Sciences buy Ruckelsbuckel
Start price
28.08.23
/
60%
€1.50
Target price
28.08.24
€6.00
Performance (%)
-6.00%
End price
05.09.23
€1.41
Summary
This prediction ended on 05.09.23 with a price of €1.41. With a performance of -6.00%, the BUY prediction by Ruckelsbuckel finished with a loss. Ruckelsbuckel has 60% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Kezar Life Sciences | 0.000% | 0.000% |
| iShares Core DAX® | -3.033% | 0.651% |
| iShares Nasdaq 100 | -3.554% | -3.007% |
| iShares Nikkei 225® | -3.938% | 1.935% |
| iShares S&P 500 | -1.517% | -0.602% |
According to Ruckelsbuckel what are the pros and cons of Kezar Life Sciences for the foreseeable future?
Pros
Very capable Management
Very good company culture
Leading role in innovation
Strong uniques
Differentiated customer and product portfolio
Growths faster than the competition
Top 10 in its market
Known brand
Sustainability is important
Management is a major shareholder
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
positive Cash Flow expected
Good rating
High Investments for future growth
Small cyclical dependencies
Future proof or reliable business model
Cons
High risks for its business
Very low/no dividend yield expected
High risks in the balance sheet
EBIT decline/stagnation expected
ROE lower than 10% per year
Increased challenges to pay loans and raise capital